Literature DB >> 18808434

Wound dressing components degrade proteins detrimental to wound healing.

Brett Baskovich1, Edith M Sampson, Gregory S Schultz, Laura K S Parnell.   

Abstract

Excessive levels of matrix metalloproteinases (MMPs) are present in chronic wounds preventing wound closure. Reducing detrimental components may be key in healing chronic wounds. Elta Protease-containing wound dressings have been observed clinically to resolve inflammation and appear to aid healing in acute and chronic recalcitrant wounds. To investigate possible mechanisms of action, in vitro tests, zymography, collagenase assays and enzyme-linked immunosorbent assays (ELISAs), were performed to evaluate the effect of the dressing proteases on detrimental and beneficial wound healing components such as MMPs, Tissue Inhibitor of Matrix Metalloproteinases (TIMPs), cytokines and growth factors. Standards of pro- and active MMP-2, MMP-9 and chronic wound fluid (CWF) were prepared. Degradation of target proteins was enhanced by increased Elta Protease concentration, temperature and incubation time. Incubation with serial dilutions of the Elta Proteases resulted in nearly complete degradation of all MMP standards. After a 30-minute incubation, twofold diluted Elta Proteases degraded >90% of the gelatinases in CWF. ELISAs showed that Elta Proteases effectively degraded MMP-9 and tumour necrosis factor (TNF-alpha). In contrast, Platelet Derived Growth Factor (PDGF) and interleukin 1 beta were resistant to degradation by Elta Proteases. These results suggest that Elta Protease dressings appear to deactivate detrimental components in CWF, which may reduce wound bed contact with harmful proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18808434      PMCID: PMC7951203          DOI: 10.1111/j.1742-481X.2007.00422.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  15 in total

1.  Contact dermatitis treated with new topical products: a case study.

Authors:  L Barnett; L K Parnell
Journal:  Ostomy Wound Manage       Date:  2001-09       Impact factor: 2.629

2.  Preliminary use of a hydrogel containing enzymes in the treatment of stage II and stage III pressure ulcers.

Authors:  Linda K S Parnell; Brandi Ciufi; Charles F Gokoo
Journal:  Ostomy Wound Manage       Date:  2005-08       Impact factor: 2.629

3.  Biochemical analysis of acute and chronic wound environments.

Authors:  R W Tarnuzzer; G S Schultz
Journal:  Wound Repair Regen       Date:  1996 Jul-Sep       Impact factor: 3.617

4.  Interactions of cytokines, growth factors, and proteases in acute and chronic wounds.

Authors:  B A Mast; G S Schultz
Journal:  Wound Repair Regen       Date:  1996-10       Impact factor: 3.617

5.  Growth factors and chronic wounds: the need to understand the microenvironment.

Authors:  V Falanga
Journal:  J Dermatol       Date:  1992-11       Impact factor: 4.005

6.  Promotion of wound repair in old mice by local injection of macrophages.

Authors:  D Danon; M A Kowatch; G S Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

7.  Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors.

Authors:  Dorne R Yager; S M Chen; S I Ward; O O Olutoye; R F Diegelmann; I Kelman Cohen
Journal:  Wound Repair Regen       Date:  1997 Jan-Mar       Impact factor: 3.617

Review 8.  Engineered growth factors and cutaneous wound healing: success and possible questions in the past 10 years.

Authors:  Xiaobing Fu; Xiaokun Li; Biao Cheng; Wei Chen; Zhiyong Sheng
Journal:  Wound Repair Regen       Date:  2005 Mar-Apr       Impact factor: 3.617

9.  A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.

Authors:  T A Mustoe; N R Cutler; R M Allman; P S Goode; T F Deuel; J A Prause; M Bear; C M Serdar; G F Pierce
Journal:  Arch Surg       Date:  1994-02

10.  Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group.

Authors:  D L Steed
Journal:  J Vasc Surg       Date:  1995-01       Impact factor: 4.268

View more
  5 in total

1.  Application of protease technology in dermatology: rationale for incorporation into skin care with initial observations on formulations designed for skin cleansing, maintenance of hydration, and restoration of the epidermal permeability barrier.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-06

2.  Hyperbaric oxygen effect on MMP-9 after a vascular insult.

Authors:  Francis J Cummins; Laurie J Gentene
Journal:  J Cardiovasc Transl Res       Date:  2010-09-08       Impact factor: 4.132

Review 3.  Engineering dextran-based scaffolds for drug delivery and tissue repair.

Authors:  Guoming Sun; Jeremy J Mao
Journal:  Nanomedicine (Lond)       Date:  2012-11       Impact factor: 5.307

4.  Protein degradation and protection observed in the presence of novel wound dressing components.

Authors:  Laura K S Parnell
Journal:  J Funct Biomater       Date:  2011-12-02

5.  Amniotic Membrane Modifies the Genetic Program Induced by TGFß, Stimulating Keratinocyte Proliferation and Migration in Chronic Wounds.

Authors:  Antonia Alcaraz; Anna Mrowiec; Carmen Luisa Insausti; Ángel Bernabé-García; Eva María García-Vizcaíno; María Concepción López-Martínez; Asunción Monfort; Ander Izeta; José María Moraleda; Gregorio Castellanos; Francisco José Nicolás
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.